News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
Following FDA approval last October, Adaptive has now secured Medicare coverage for its NGS-based minimal residual disease assay, ClonoSeq.
Despite initial promise, NGS-based MRD detection has not been broadly adopted, but improvements in technology and more clinical utility data may change that.
Within the country's first whole-genome sequencing program, researchers hope to initially focus on identifying markers associated with hereditary diseases and cancer risk.
NorthShore University HealthSystem is among the first of many interested in implementing genetic testing and tracking the population health impact, according to Color.
Lineagen hopes to use PWNHealth's consumer-oriented model to expand access to its testing services for developmental delay and autism spectrum disorder.
